about
In-vivo multi-exponential T2, magnetization transfer and quantitative histology in a rat model of intramyelinic edema.Transient focal lesion in the splenium of the corpus callosum: MR imaging with an attempt to clinical-physiopathological explanation and review of the literature.Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.The potential for vigabatrin-induced intramyelinic edema in humans.Effects of vigabatrin on evoked potentials in epileptic patients.Visual field defects associated with vigabatrin therapy.Pharmacology of vigabatrin.Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?Treatment of refractory complex partial seizures: role of vigabatrin.Overview of the safety of newer antiepileptic drugs.Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration.Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.Vigabatrin visual toxicity: evolution and dose dependence.Vigabatrin (gamma-vinyl-GABA): neuropathologic evaluation in five patients.Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy.Open, double-blind and long-term study of vigabatrin in chronic epilepsy.Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor.Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy
P2860
Q30687567-34DE6479-3CAF-4E79-8517-CB54EBA2BF38Q31130552-F259ACB3-5BD9-4662-A134-64661B0D4AAAQ31366135-FC21E7BB-F3CB-4F0F-A7B8-A50D47DCC79FQ31535676-87B1A06C-B568-49C5-BD34-F264AEE9D5A8Q34396870-294C659D-4DE3-4FF1-8BB7-F44FB08BF99DQ35454439-A412763C-D18A-49BF-A9CF-60F716D0A2CAQ36223272-7BAD8034-C167-47AA-B861-1A1EFA501AD6Q37431730-8B07D96E-8E55-448F-B0A1-262CCE95BBF2Q37620193-C2C49590-8BD3-44A6-ADF0-E79027A0B800Q41418008-8670CD61-D88C-40BD-9FC0-33CF3A36139DQ43272828-A1A13577-5FCE-4F20-932B-FED1252FA1D3Q43509864-B39AE7B4-C982-4D60-ACD8-8417F02C5F43Q43622918-EB6F0CF1-4380-4AE5-8D7C-47DEB506A5FBQ48363107-E82BE86E-8B50-48CF-840C-F5B7FF420995Q48437669-B28E8723-866B-4AF3-BEA6-C1124E285148Q48903818-BD45CD13-1BDD-40A0-A4DB-4CE00231F46DQ54231363-8C73311E-F4F6-44CF-BA0D-06748C8DFEB6Q54232900-6B0FD00C-88B9-40BB-B31F-919FCFFAC2BCQ57626540-0D941D96-B57B-4C52-A805-647EF6E4665C
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Neuropathology of vigabatrin.
@en
type
label
Neuropathology of vigabatrin.
@en
prefLabel
Neuropathology of vigabatrin.
@en
P2860
P1476
Neuropathology of vigabatrin.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1989.TB03460.X
P407
P478
27 Suppl 1
P577
1989-01-01T00:00:00Z